{"nctId":"NCT01143077","briefTitle":"A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents","startDateStruct":{"date":"2010-06"},"conditions":["Schizophrenia","Schizoaffective Disorder"],"count":244,"armGroups":[{"label":"Lurasidone Open-Label Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]},{"label":"Lurasidone Open-Label Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]},{"label":"Lurasidone Open-Label Arm C","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]}],"interventions":[{"name":"Lurasidone HCl","otherNames":["Latuda"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject â‰¥ 18 years of age.\n* Subject meets DSM-IV criteria for a primary diagnosis of schizophrenia or schizoaffective disorder.\n* Subject must be judged by the investigator to be an appropriate candidate for switching current antipsychotic medication due to insufficient efficacy and/or safety or tolerability concerns.\n\nExclusion Criteria:\n\n* Presence of an Axis I or Axis II disorder other than schizophrenia or schizoaffective disorder that is the primary focus of treatment prior to screening.\n* Subject has experienced persistent lack of improvement in psychotic symptoms despite adequate trials (at least 6 weeks at standard doses), of two or more antipsychotic agents in the 12 months prior to screening.\n* Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or property. Subject has suicidal ideation at baseline or has attempted suicide within 90 days prior to randomization (even without hospitalization).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Relapse of Psychotic Symptoms During 6 Weeks","description":"Relapse is defined as any occurrence of:\n\n* Insufficient clinical response\n* Exacerbation of underlying disease\n* Discontinuation due to an adverse event","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":"12.1"},{"groupId":"OG001","value":"16.9","spread":"11.6"},{"groupId":"OG002","value":"17.3","spread":"8.9"}]}]}]},{"type":"SECONDARY","title":"Tolerability and Safety","description":"Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":72},"commonTop":["Nausea","Insomnia","Akathisia","Headache","Vomiting"]}}}